Michal Sternschuss

Delivering a crisp, practice-ready roadmap with @jackiebrown_MD for optimal sequencing after EV+pembro progression ==> grounding choices in actionable biomarkers, real-world tolerability, and evidence in the field #AUC3 #BladderCancer @AUC3_Official @OncoAlert @mzugman @MichalSternsch @weoncologists

Technical advances and overall patient selection strategies thoughtfully highlighted with @l_ballas - - the details that determine whether local strategies succeed or fail in NMIBC. #AUC3 #BladderCancer @AUC3_Official @OncoAlert @mzugman @MichalSternsch @weoncologists

Debate time on response monitoring with ctDNA: Pro #DrAlexandraDrakaki from @UCLAHealth vs Con @OncoBellmunt ||| what should define response, and what’s enough to change course? #AUC3 #BladderCancer @AUC3_Official @OncoAlert @mzugman @MichalSternsch @weoncologists

Thoughtful discussion of evidence-based adjuvant approaches for urothelial carcinoma by @Dr_Aggen at @AUC3_Official @OncoAlert

Great start to the day with Dr. @WesleyYipMD at #AUC3, opening the discussion on intermediate-risk non-muscle invasive bladder cancer and the implications of further risk stratification within this group. @OncoAlert @Mustafajsalehmd @DrRosenbergMSK

Session 1 in #BladderCancer with our scientific chairs @UroDocAsh and #DrSethlerner @AUC3_Official Beyond BCG next generation approaches to NMIBC. #AUC3 #KidneyCancer @AUC3_Official @OncoAlert @mzugman @MichalSternsch @weoncologists

Day 1 at @AUC3_Official began with a focused look at localized RCC, exploring how evolving clinical and molecular diagnostics—from pathology to emerging biomarkers—are influencing preoperative treatment decisions. A closing panel examined how these tools translate into real-world care and what’s coming next. Special thank you to all our panelists! #AUC3 #AUC3Miami #KidneyCancer #GUOncology #UrologyCare #CancerTreatmentAdvances #OncologyExperts #ClinicalDebate #CancerResearch #MedicalInnovation @DrRanaMcKay @Drchoueiri @montypal @DrRosenbergMSK @MichelleDunno17 @TiansterZhang @brian_rini @VincentWenxinXu @BraunMDPhD @crisuarez08 @motzermd @maughanonc

A classic RCC debate in the second session at #AUC3: IO/IO vs IO/TKI. A high-level exchange between Dr. Atkins and Dr. @motzermd. In the same panel, key insights on treating IO-resistant disease and TKI sequencing from Dr. @maughanonc. @OncoAlert

Session 1 on localized RCC at @AUC3_Official opened Day 1 with a deep dive into preoperative decision‑making in kidney cancer. Faculty reviewed how clinical, pathologic, and molecular tools—including IHC, FISH, NGS, and emerging biomarkers such as KIM‑1 and ctDNA—can refine risk stratification and guide neoadjuvant and adjuvant strategies. The session concluded with a panel discussion that brought together diverse expert perspectives on applying these diagnostics in real‑world practice, highlighting both current evidence and the next frontiers for biomarker‑driven care. @OncoAlert @DrRanaMcKay @DrChoueiri @DrRosenbergMSK @montypal @MichelleDunno17 @TiansterZhang @utswcancer @LombardiCancer @brian_rini @VincentWenxinXu @DanaFarber #AUC3 #AUC3Miami #KidneyCancer #GUOncology #UrologyCare #CancerTreatmentAdvances #OncologyExperts #ClinicalDebate #CancerResearch #MedicalInnovation

Adjuvant therapy debate with @brian_rini and #DrAtkins. Preventing recurrence vs delaying recurrence. Benefit risk equation in resected high-risk RCC is real. Pembro shows a clear DFS signal, but toxicity and «what happens at recurrence» still matter vs observation. Biomarker driven selection/stratification (ctDNA/KIM-1/…) is the next step @VincentWenxinXu. @OncoAlert @weoncologists @mzugman @MichalSternsch

Session 1: Localized RCC session kicking off now with our scientific chairs #DrAxelBex and @NaomiHaas5. Seting the stage with pre meeting questions and the big theme. @AUC3_Official @OncoAlert @mzugman @weoncologists @MichalSternsch

🚨 Major win for patients with muscle-invasive bladder cancer! The FDA has approved EV + Pembrolizumab as perioperative therapy for patients who are cisplatin-ineligible — a huge step forward in improving outcomes and expanding treatment options. 🔗 Read the full FDA announcement: fda.gov/drugs/resource… #BladderCancer #UroOnc #CancerResearch #FDAApproved #MedTwitter @OncoAlert

Big news- FDA approves EV/Pembro for patients with MIBC who are cisplatin ineligible! The needle moves. Great news for patients! fda.gov/drugs/resource… @bbmdmsk @Dr_Aggen @shilpaonc @PGrivasMDPhD @DrChoueiri @montypal @apolo_andrea

The UromigosLive 2025 meeting presents #UromigosShorts videos on GU Oncology topics. The videos with the most views win a prize at #UromigosLive November 7-8th in Nashville, TN. Below, Dr. David Aggen discusses : Variant Histology Bladder Cancer.

Quality of Informed Consent via #Telemedicine Compared With In-Person for Clinical Cancer Research: brnw.ch/21wTOtn Authored by @MichalSternsch, @VickersBiostats, et al. @MSKCancerCenter

🎥  #ASCO2025 GU Poster! @Alyssa_arbuiso (MSKCC): ✔️ Skin toxicity ≠ response marker (EV+P) ✔️ Confounders negate correlation 👀 Watch now bit.ly/4mLvOXR #MediMix #EVplusP #BladderCancer

🎥  #ASCO2025 GU Poster! Dr @MichalSternsch: ✔️ Post-EV+P platinum → ORR 49% ✔️ PFS: 4.6 mo | OS: 11 mo 👀 Watch now bit.ly/4mLvOXR #MediMix #BladderCancer #Platinum

Quality of Informed Consent via #Telemedicine Compared With In-Person for Clinical #Cancer Research. ascopubs.org/doi/10.1200/OP… @ASCO @JCO_ASCO @JCOOP_ASCO #CancerResearch #Telehealth @MSKCancerCenter @VickersBiostats

Real-world clinical outcomes of sacituzumab govitecan after prior exposure to enfortumab vedotin in pts with metastatic urothelial carcinoma in @ESMO_Open. In a large RW cohort, treatment with SG after prior EV resulted in limited clinical efficacy. esmoopen.com/article/S2059-…

@Uromigos #asco25 Unsung Hero Poster Award for bladder cancer. @MichalSternsch presents some data for outcomes of therapy after EVP. Watch to the end for the applause!